The results of the RE-LY study promise more effective, safer and easier prevention of embolic complications in patients with non-valvular artial fibrillation

Abstract

The RE-LY study compared dabigatran in the dose of 150 mg and 110 mg twice daily, without laboratory monitoring, with the conventional trratment with warfarin dosed according to INR in 18,113 patients with non-valvular atrial fibrillation and high risk of embolisation.

Keywords

• non-valvular atrial fibrillation
• cerebrovascular event
• systemic embolisation